Literature DB >> 23782895

Cognitive findings and behavior in children and adolescents with phenylketonuria.

Simona Cappelletti1, Giovanna Cotugno, Bianca M Goffredo, Rosanna Nicolò, Silvia M Bernabei, Stefania Caviglia, Vincenzo Di Ciommo.   

Abstract

OBJECTIVE: The primary aim of this study was to assess cognitive development, in particular that of executive functions (EFs), and behavioral findings for patients with early treated phenylketonuria (PKU). Furthermore, we evaluated the relationships of our findings with plasma levels of Phe and adherence to dietary prescriptions.
METHODS: A cross-sectional design was adopted. Patients who had early treated PKU, who were older than 4 years, and who were regularly seen by a physician were enrolled in the study. Cognitive development was assessed with Wechsler Scales appropriate to the chronological age of subjects in the study. Executive functions were assessed using the Tower of London test, and behavioral findings were quantified with the Child Behavior Checklist.
RESULTS: Thirty-five patients were enrolled (mean age 11.5 years, SD ± 6.2). The mean Full Scale intelligence quotient was in the normal range (93.4 ± 17.4), without significant difference between the verbal intelligence quotient (mean, 94.3 ± 16.1) and performance intelligence quotient (mean, 93.9 ± 18.0). The majority of patients showed a deficit within the EF domain of cognitive abilities (mean lower than 1.8 SD of the normal mean), 8 of them showing a score <2 SD lower than the normal mean. Internalizing problems were also observed in 12 patients (38.7%) and were higher in adherent patients and in patients with a lower intelligence quotient.
CONCLUSION: After early diagnosis and treatment of PKU, residual problems can be found in EFs of patients not achieving satisfactory Phe levels, while scores of internalizing behaviors were higher in compliant patients.

Entities:  

Mesh:

Year:  2013        PMID: 23782895     DOI: 10.1097/DBP.0b013e31829a79ef

Source DB:  PubMed          Journal:  J Dev Behav Pediatr        ISSN: 0196-206X            Impact factor:   2.225


  6 in total

1.  Characterization of 2-(methylamino)alkanoic acid capacity to restrict blood-brain phenylalanine transport in Pah enu2 mice: preliminary findings.

Authors:  Kara R Vogel; Erland Arning; Brandi L Wasek; Teodoro Bottiglieri; K Michael Gibson
Journal:  Mol Genet Metab       Date:  2013-08-15       Impact factor: 4.797

2.  Parenting a Child with Phenylketonuria: An Investigation into the Factors That Contribute to Parental Distress.

Authors:  Olivia Ambler; Emma Medford; Dougal J Hare
Journal:  JIMD Rep       Date:  2018-04-20

Review 3.  The complete European guidelines on phenylketonuria: diagnosis and treatment.

Authors:  A M J van Wegberg; A MacDonald; K Ahring; A Bélanger-Quintana; N Blau; A M Bosch; A Burlina; J Campistol; F Feillet; M Giżewska; S C Huijbregts; S Kearney; V Leuzzi; F Maillot; A C Muntau; M van Rijn; F Trefz; J H Walter; F J van Spronsen
Journal:  Orphanet J Rare Dis       Date:  2017-10-12       Impact factor: 4.123

4.  Long-Term Follow-Up of Cognition and Mental Health in Adult Phenylketonuria: A PKU-COBESO Study.

Authors:  Rianne Jahja; Francjan J van Spronsen; Leo M J de Sonneville; Jaap J van der Meere; Annet M Bosch; Carla E M Hollak; M Estela Rubio-Gozalbo; Martijn C G J Brouwers; Floris C Hofstede; Maaike C de Vries; Mirian C H Janssen; Ans T van der Ploeg; Janneke G Langendonk; Stephan C J Huijbregts
Journal:  Behav Genet       Date:  2017-08-03       Impact factor: 2.805

5.  Behavioral and Emotional Problems in Early-Treated Brazilian Children and Adolescents with Phenylketonuria.

Authors:  Eduardo Vieira Neto; Heber de Souza Maia Filho; Claudia Braga Monteiro; Lilian de Mattos Carvalho; Thuane Silva da Cruz; Belisia Vasconcelos de Barros; Marcia Gonçalves Ribeiro
Journal:  Med Sci Monit       Date:  2018-10-30

6.  Executive functioning, adaptive skills, emotional and behavioral profile: A comparison between autism spectrum disorder and phenylketonuria.

Authors:  Barbara Trimarco; Filippo Manti; Francesca Nardecchia; Sergio Melogno; Mara Testa; Giovanni Meledandri; Claudia Carducci; Roberta Penge; Vincenzo Leuzzi
Journal:  Mol Genet Metab Rep       Date:  2020-03-09
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.